<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01273857</url>
  </required_header>
  <id_info>
    <org_study_id>MHLW10103228</org_study_id>
    <nct_id>NCT01273857</nct_id>
  </id_info>
  <brief_title>Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single Ventricle Physiology</brief_title>
  <acronym>TICAP</acronym>
  <official_title>Phase I Study of Cardiac Progenitor Cell Therapy in Patients With Single Ventricle Physiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Okayama University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cerebral and Cardiovascular Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Okayama University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoplastic left heart syndrome (HLHS) and related anomalies involved a single ventricle are
      characterized by hypoplasia of the left heart and the aorta with compromised systemic cardiac
      output. Infants with the syndrome generally undergo a staged surgical approach in view of an
      ultimate Fontan procedure. Although long-term survival in patients with HLHS and related
      single ventricle physiology has improved markedly with advances in medical and surgical
      therapies, a growing number of infants will ultimately require heart transplantation for
      end-stage heart failure due to several potential disadvantages include a negative effect on
      right ventricular function, arrhythmia, additional volume load via regurgitation from the
      nonvalved shunt, and impaired growth of the pulmonary artery.

      Risk factors for poor outcome of heart transplantation with HLHS and single ventricle
      physiology are older age at transplantation and previous Fontan operation. New strategies are
      needed to improve the underlying transplant risks proper for the Fontan failure patients.

      Emerging evidence suggests that heart-derived stem/progenitor cells can be used to improved
      cardiac function in patients with ischemic heart disease. In this trial, the investigators
      aimed to test the safety and feasibility of intracoronary injection of autologous cardiac
      progenitor cells in patients with HLHS and related single ventricle anomalies and that could
      improve ventricular function at 3 months' follow up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autologous cardiac progenitor cells are isolated from patients' own cardiac tissues obtained
      during palliative shunt procedure. Patients will receive 0.3 million/kg of autologous cardiac
      progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3
      months to 1 year after cell injection will need to prospectively verify the clinical,
      laboratory, and safety-related data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells</measure>
    <time_frame>3 months to 1 year after cell transplantation</time_frame>
    <description>Feasibility was assessed by number of participants discontinued the study due to adverse events or number of participants received unsuccessful cell delivery by study physician. Unsuccessful was defined as failure of coronary selection of guiding catheter or direct cell infusion.
The primary end point is to monitor major adverse cardiac events include death, sustained/symptomatic ventricular tachycardia, aggravation of heart failure, new myocardial infarction, unplanned cardiovascular operation for cardiac tamponade and infection in the first month after injection, and serially afterwards.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>3 months to 1 year after cell transplantation</time_frame>
    <description>The incidence of hospitalization for heart failure, ventricular arrhythmia, general infection, and renal and hepatic dysfunction by CDC treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Hypoplastic Left Heart Syndrome</condition>
  <condition>Single Ventricle</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects will undergo standard staged-procedures without cell infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cell infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive transcoronary infusion of autologous cardiosphere-derived cells 1 month after staged shunt procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous cardiac progenitor cell transplantation</intervention_name>
    <description>Patients will receive 0.3 million / kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.</description>
    <arm_group_label>Cell infusion</arm_group_label>
    <other_name>Cardiosphere-derived cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>staged shunt procedure</intervention_name>
    <description>Norwood-Glenn, Glenn, or Fontan procedure will be applied</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Cell infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants with hypoplastic left heart syndrome and related single ventricle anomalies
             undergoing first to third palliative shunt surgeries will be recruited into the study.

          -  Patients between 0 and 6 years of age are eligible if written informed consent can be
             obtained.

        Exclusion Criteria:

          -  Cardiogenic shock

          -  Eisenmenger syndrome

          -  Uncontrollable arrhythmia

          -  Severe chronic diseases

          -  Infections

          -  Cancer

          -  Unwillingness to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hidemasa Oh, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Regenerative Medicine, Center for Innovative Clinical Medicine, Okayama University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Regenerative Medicine, Center for Innovative Clinical Medicine, Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Takehara N, Tsutsumi Y, Tateishi K, Ogata T, Tanaka H, Ueyama T, Takahashi T, Takamatsu T, Fukushima M, Komeda M, Yamagishi M, Yaku H, Tabata Y, Matsubara H, Oh H. Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J Am Coll Cardiol. 2008 Dec 2;52(23):1858-65. doi: 10.1016/j.jacc.2008.06.052.</citation>
    <PMID>19038683</PMID>
  </reference>
  <reference>
    <citation>Tateishi K, Takehara N, Matsubara H, Oh H. Stemming heart failure with cardiac- or reprogrammed-stem cells. J Cell Mol Med. 2008 Dec;12(6A):2217-32. doi: 10.1111/j.1582-4934.2008.00487.x. Epub 2008 Aug 27. Review.</citation>
    <PMID>18754813</PMID>
  </reference>
  <reference>
    <citation>Tateishi K, Ashihara E, Takehara N, Nomura T, Honsho S, Nakagami T, Morikawa S, Takahashi T, Ueyama T, Matsubara H, Oh H. Clonally amplified cardiac stem cells are regulated by Sca-1 signaling for efficient cardiovascular regeneration. J Cell Sci. 2007 May 15;120(Pt 10):1791-800.</citation>
    <PMID>17502484</PMID>
  </reference>
  <reference>
    <citation>Tateishi K, Ashihara E, Honsho S, Takehara N, Nomura T, Takahashi T, Ueyama T, Yamagishi M, Yaku H, Matsubara H, Oh H. Human cardiac stem cells exhibit mesenchymal features and are maintained through Akt/GSK-3beta signaling. Biochem Biophys Res Commun. 2007 Jan 19;352(3):635-41. Epub 2006 Nov 27.</citation>
    <PMID>17150190</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2011</study_first_posted>
  <results_first_submitted>April 21, 2015</results_first_submitted>
  <results_first_submitted_qc>June 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 15, 2015</results_first_posted>
  <last_update_submitted>June 12, 2015</last_update_submitted>
  <last_update_submitted_qc>June 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Okayama University</investigator_affiliation>
    <investigator_full_name>Hidemasa Oh</investigator_full_name>
    <investigator_title>MD., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Cardiac progenitor cells</keyword>
  <keyword>Cell therapy</keyword>
  <keyword>Hypoplastic Left Heart Syndrome</keyword>
  <keyword>Single Ventricle</keyword>
  <keyword>Norwood</keyword>
  <keyword>Sano modification</keyword>
  <keyword>Glenn</keyword>
  <keyword>Fontan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hypoplastic Left Heart Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Subjects will undergo standard staged-procedures without cell infusion
staged shunt procedure: Norwood-Glenn, Glenn, or Fontan procedure will be applied</description>
        </group>
        <group group_id="P2">
          <title>Cell Infusion</title>
          <description>Subjects will receive transcoronary infusion of autologous cardiosphere-derived cells 1 month after staged shunt procedure
Autologous cardiac progenitor cell transplantation: Patients will receive 0.3 million / kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.
staged shunt procedure: Norwood-Glenn, Glenn, or Fontan procedure will be applied</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Subjects will undergo standard staged-procedures without cell infusion
staged shunt procedure: Norwood-Glenn, Glenn, or Fontan procedure will be applied</description>
        </group>
        <group group_id="B2">
          <title>Cell Infusion</title>
          <description>Subjects will receive transcoronary infusion of autologous cardiosphere-derived cells 1 month after staged shunt procedure
Autologous cardiac progenitor cell transplantation: Patients will receive 0.3 million / kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.
staged shunt procedure: Norwood-Glenn, Glenn, or Fontan procedure will be applied</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.5" spread="1.7"/>
                    <measurement group_id="B2" value="2.1" spread="1.2"/>
                    <measurement group_id="B3" value="1.7" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells</title>
        <description>Feasibility was assessed by number of participants discontinued the study due to adverse events or number of participants received unsuccessful cell delivery by study physician. Unsuccessful was defined as failure of coronary selection of guiding catheter or direct cell infusion.
The primary end point is to monitor major adverse cardiac events include death, sustained/symptomatic ventricular tachycardia, aggravation of heart failure, new myocardial infarction, unplanned cardiovascular operation for cardiac tamponade and infection in the first month after injection, and serially afterwards.</description>
        <time_frame>3 months to 1 year after cell transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subjects will undergo standard staged-procedures without cell infusion
staged shunt procedure: Norwood-Glenn, Glenn, or Fontan procedure will be applied</description>
          </group>
          <group group_id="O2">
            <title>Cell Infusion</title>
            <description>Subjects will receive transcoronary infusion of autologous cardiosphere-derived cells 1 month after staged shunt procedure
Autologous cardiac progenitor cell transplantation: Patients will receive 0.3 million / kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.
staged shunt procedure: Norwood-Glenn, Glenn, or Fontan procedure will be applied</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells</title>
          <description>Feasibility was assessed by number of participants discontinued the study due to adverse events or number of participants received unsuccessful cell delivery by study physician. Unsuccessful was defined as failure of coronary selection of guiding catheter or direct cell infusion.
The primary end point is to monitor major adverse cardiac events include death, sustained/symptomatic ventricular tachycardia, aggravation of heart failure, new myocardial infarction, unplanned cardiovascular operation for cardiac tamponade and infection in the first month after injection, and serially afterwards.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events</title>
        <description>The incidence of hospitalization for heart failure, ventricular arrhythmia, general infection, and renal and hepatic dysfunction by CDC treatment.</description>
        <time_frame>3 months to 1 year after cell transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subjects will undergo standard staged-procedures without cell infusion
staged shunt procedure: Norwood-Glenn, Glenn, or Fontan procedure will be applied</description>
          </group>
          <group group_id="O2">
            <title>Cell Infusion</title>
            <description>Subjects will receive transcoronary infusion of autologous cardiosphere-derived cells 1 month after staged shunt procedure
Autologous cardiac progenitor cell transplantation: Patients will receive 0.3 million / kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.
staged shunt procedure: Norwood-Glenn, Glenn, or Fontan procedure will be applied</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>The incidence of hospitalization for heart failure, ventricular arrhythmia, general infection, and renal and hepatic dysfunction by CDC treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Subjects will undergo standard staged-procedures without cell infusion
staged shunt procedure: Norwood-Glenn, Glenn, or Fontan procedure will be applied</description>
        </group>
        <group group_id="E2">
          <title>Cell Infusion</title>
          <description>Subjects will receive transcoronary infusion of autologous cardiosphere-derived cells 1 month after staged shunt procedure
Autologous cardiac progenitor cell transplantation: Patients will receive 0.3 million / kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.
staged shunt procedure: Norwood-Glenn, Glenn, or Fontan procedure will be applied</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Hidemasa Oh</name_or_title>
      <organization>Okayama University Hospital</organization>
      <phone>+81-086-235-6506</phone>
      <email>hidemasa@md.okayama-u.ac.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

